TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/3/24 19:48 | 5/3/24 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Grygiel Nancy A. | CA | O | SVP,CCO | S | -663 | 313.09 | 0 | -2 | -17 | 10 | D | ||||||||||||||
12/4/23 19:41 | 12/4/23 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Grygiel Nancy A. | CA | O | SVP,CCO | S | -572 | 273.03 | 0 | -2 | -16 | 11 | D | ||||||||||||||
11/8/22 18:38 | 11/8/22 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Grygiel Nancy A. | CA | O | SVP,CCO | S | -160 | 293.54 | 0 | -1 | -4 | 13 | D | ||||||||||||||
5/12/21 20:10 | 5/11/21 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Grygiel Nancy A. | CA | O | SVP,CCO | M.d | 407 | 162.60 | 0 | 3 | 25 | 13 | D | ||||||||||||||
5/12/21 20:10 | 5/11/21 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Grygiel Nancy A. | CA | O | SVP,CCO | S.d | -631 | 252.51 | 0 | -3 | -17 | 13 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |